Journal of Clinical Oncology
Articles in this Issue
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study
PURPOSE SERENA-3 is a presurgical window-of-opportunity (WOO) trial exploring the pharmacodynamic effects of camizestrant in postmenopausal women with newly diagnosed estrogen rece...
WBC Growth Factors: ASCO Guideline Update
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the...
Is Heavy Alcohol Use Associated With Young-Onset Pancreatic Cancer?
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
In this 5-year follow-up from the CheckMate 743 study in patients with unresectable pleural mesothelioma (PM), we evaluated updated efficacy and safety outcomes and biomarkers and performed treatment-...
Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age 20-39 Years
PURPOSE The incidence of young-onset pancreatic cancer has increased rapidly; however, the dose-response relationship between alcohol consumption and the risk of incident young-ons...
Windows of Opportunity in Breast Cancer: Learning More From Fewer Patients in a Shorter Time
Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose Chemotherapy
PURPOSE High-dose chemotherapy (HDCT) is one of the salvage therapy options for patients with relapsed/refractory germ cell tumors (rGCT) after failure of first-line chemotherapy....
Bridging the Gap: Induction Nivolumab Before Chemoradiation in Intermediate/High-Risk Human Papillomavirus–Driven Oropharyngeal Squamous Cell Carcinoma
The Power of “I Don't Know”
A reflection by @SondosZayedMD on the unexpected power of saying “I don't know”—and how honest uncertainty can deepen trust, guide care, and create space for what truly matters in oncology. #JCO @JCO_...
Reply to: Can Pathologic Complete Response Serve as a Valid Surrogate End Point?
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)
PURPOSE Angiogenesis plays an essential role in neuroendocrine tumors (NETs). This study evaluates efficacy and safety of axitinib in extrapancreatic (ep)-NETs....
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus–Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial
PURPOSE Patients with human papillomavirus (HPV)–positive oropharyngeal cancer (OPC) and advanced stage and/or significant smoking history are at higher risk of relapse. Induction...